Published in:
01-10-2019 | Lymphoma | Letter to the Editor
Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib
Authors:
Annie Pang, Rex Au-Yeung, Rock Y.Y. Leung, Yok-Lam Kwong
Published in:
Annals of Hematology
|
Issue 10/2019
Login to get access
Excerpt
Primary cutaneous diffuse large B cell lymphoma leg type (PCLBCL-LT) is a rare malignancy occurring predominantly below the knee, but may involve other cutaneous and extra-cutaneous sites [
1]. Lymphoma cells typically express CD20, CD79A, BCL2, BCL6, MUM-1, and FOXP1, but not CD10 [
1,
2]. Gene expression of PCLBCL-LT resembled activated B cell diffuse large B cell lymphoma (ABC-DLBCL). Consequently, genes involved in NF-κB activation were frequently mutated [
3], with the
MYD88 L265P mutation most prevalent, found in 60–80% of cases [
3]. …